# Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer

> **NCT03251365** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hospital General de Ciudad Real** · enrollment: 42 (estimated)

## Conditions studied

- Resectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** HIPEC-gemcitabine

## Key facts

- **NCT ID:** NCT03251365
- **Lead sponsor:** Hospital General de Ciudad Real
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-27
- **Primary completion:** 2020-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251365, "Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03251365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*